Prognostic markers of low-grade squamous intraepithelial lesions: the role of topoisomerase IIα and active caspase-3

Purpose: To study the relationship between topoisomerase II alpha, active caspase-3 expressions and HPV DNA in uterine cervices with low-grade squamous intraepithelial lesions (LSIL). Methods: Forty women with LSIL and 32 without cervical neoplasia diagnosed through cytologic and histopathologic examination were evaluated regarding topoisomerase II alpha and active caspase-3 expressions and HPV DNA detection using PCR (GP5/GP6) in cervicovaginal smears. Results: The mean percentage of cells immunomarked by topoisomerase in the group with LSIL was 11.62% while in the control it was 4.13% (p < 0.0001). In the presence of HPV DNA, topoisomerase expression was higher in the group With productive viral infection than in nonneoplastic tissue (p = 0.004). Caspase-3 expression was observed in 17 patients with LSIL (42.5%) and in five without cervical neoplasia (15.63%). Conclusion: The use of topoisomerase II alpha and active caspase-3 in cervical biopsies may help to define the prognosis of HPV cervical infection.

Topoisomerase II alpha; Caspase-3; HPV; Neoplasia

[1] Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S. et al.: “Prevalence of HPV infection among females in the United States”. JAMA, 2007, 297, 813.

[2] Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A. et al.: “Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia”. JAMA, 2001, 286, 3106.

[3] von Knebel Doeberitz M.: “New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections”. Eur. J. Cancer, 2002, 38, 2229.

[4] Hsiang T.S.: “DNA topoisomerases”. Curr. Opin. Cell. Biol., 1992, 4, 396.

[5] McLeod H.L., Douglas F., Oates M., Symonds R.P., Prakash D., Van Der Zee A.G.J. et al.: “Topoisomerase I and II activity in human breast, cervix, lung and colon cancer”. Int. J. Cancer, 1994, 59, 607.

[6] Walker F., Adle-Biassette H., Madelenat P., Hénin D., Lehy T.: “Increased apoptosis in cervical intraepithelial neoplasia associated with HIV infection: implication of oncogenic human papillomavirus, caspases, and Langerhans cells”. Clin. Cancer Res., 2005, 11, 2451.

[7] Horta M.F., Young J.D.: “Quando a célula programa a própria morte”. Ci Hoje., 1999, 25, 38.

[8] El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Wani A.A.: “Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells”. Int. J. Cancer, 2005, 117, 409.

[9] Thornberry N.A., Lazebnik Y.: “Caspases: enemies within”. Science, 1998, 281, 1312.

[10] Liang Y., Yan C., Schor N.F.: “Apoptosis in the absensce of caspase 3”. Oncogene, 2001, 20, 6570.

[11] Hafian H., Venteo L., Sukhanova A., Nabiev I., Lefevre B., Pluot M.: “Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas”. Hum. Pathol., 2004, 35, 745.

[12] Villa L.L., Franco E.L.F.: “Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil”. J. Natl. Cancer Inst., 1989, 81, 332.

[13] Duttagupta C., Basu J., Ray M., Romney S.L.: “Apoptotic changes in cervical intraepithelial neoplasia”. Gynecol. Obstet. Invest., 2001, 52, 38.

[14] Grce M., Husnjak K., Bozikov J., Magdic L., Zlacki M., Lukac J., et al.: “Evaluation of genital human papillomavirus infections by polymerase chain reaction among Croatian women”. Anticancer Res., 2001, 21, 579.

[15] Camara G.N., Cerqueira D.M., Oliveira A.P., Silva E.O., Carvalho L.G., Martins C.R.: “Prevalence of human papillomavirus types in women with pre-neoplastic and neoplastic cervical lesions in the Federal District of Brazil”. Mem. Inst. Oswaldo Cruz., 2003, 98, 879.

[16] Kulmala S.M., Syrjanen S., Shabalova I., Petrovichev N., Kozachenzo V., Podistov J. et al.: “Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tool”. J. Clin. Microbiol., 2004, 42, 2470.

[17] Da Silva T.T., Guimarães M.L., Barbosa M.I.C., Pinheiro M.F.G., Maia A.F.: “Identificação de tipos de papilomavírus e de outros fatores de risco para neoplasia intraepitelial cervical”. Rev. Bras. Ginecol. Obstet., 2006, 28, 285.

[18] Yokoyama M., Iwasaka T., Nagata C., Nozawa S., Sekiya S., Hirai Y. et al.: “Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia: a cohort study in Japan”. Cancer Lett., 2003, 192, 171.

[19] Burger M.P., Hollema H., Pieters W.J., Schroder F.P., Quint W.G.: “Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus”. Br. J. Cancer, 1996, 73, 831.

[20] Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C. et al.: “The carcinogenicity of human papillomavirus types reflects viral evolution”. Virology, 2005, 337, 76.